Barclays PLC Purchases 54,257 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Barclays PLC raised its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 418.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,222 shares of the specialty pharmaceutical company's stock after purchasing an additional 54,257 shares during the period. Barclays PLC owned approximately 0.14% of KalVista Pharmaceuticals worth $778,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of KalVista Pharmaceuticals by 67.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company's stock worth $96,000 after acquiring an additional 3,328 shares during the last quarter. Intech Investment Management LLC bought a new position in KalVista Pharmaceuticals in the 3rd quarter valued at approximately $126,000. SG Americas Securities LLC acquired a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $153,000. Quest Partners LLC acquired a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $175,000. Finally, Evoke Wealth LLC bought a new stake in shares of KalVista Pharmaceuticals during the second quarter worth $181,000.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ KALV traded up $0.39 during midday trading on Thursday, reaching $8.25. The stock had a trading volume of 343,132 shares, compared to its average volume of 275,753. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $16.88. The company's 50 day moving average price is $9.17 and its 200 day moving average price is $11.21. The firm has a market cap of $407.70 million, a price-to-earnings ratio of -2.27 and a beta of 0.86.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on KALV shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Finally, Bank of America started coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a "buy" rating and a $22.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $25.00.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the sale, the insider now owns 94,199 shares in the company, valued at $872,282.74. The trade was a 7.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the business's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $133,344.00. Following the transaction, the chief executive officer now owns 266,598 shares in the company, valued at $2,468,697.48. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,291 shares of company stock valued at $304,086. 10.50% of the stock is currently owned by insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).